Literature DB >> 28247064

Genome-wide association study identifies four novel loci associated with Alzheimer's endophenotypes and disease modifiers.

Yuetiva Deming1, Zeran Li1, Manav Kapoor2, Oscar Harari1, Jorge L Del-Aguila1, Kathleen Black1, David Carrell1, Yefei Cai1, Maria Victoria Fernandez1, John Budde1, Shengmei Ma1, Benjamin Saef1, Bill Howells1, Kuan-Lin Huang3,4, Sarah Bertelsen2, Anne M Fagan5,6,7, David M Holtzman5,6,7,8, John C Morris5,6,7,8, Sungeun Kim9,10, Andrew J Saykin9, Philip L De Jager11,12,13, Marilyn Albert14, Abhay Moghekar14, Richard O'Brien15, Matthias Riemenschneider16, Ronald C Petersen17, Kaj Blennow18,19, Henrik Zetterberg18,19,20, Lennart Minthon21, Vivianna M Van Deerlin22, Virginia Man-Yee Lee22, Leslie M Shaw22, John Q Trojanowski22, Gerard Schellenberg22, Jonathan L Haines23, Richard Mayeux24, Margaret A Pericak-Vance25, Lindsay A Farrer26, Elaine R Peskind27,28, Ge Li27,29, Antonio F Di Narzo30, John S K Kauwe31, Alison M Goate2, Carlos Cruchaga32,33.   

Abstract

More than 20 genetic loci have been associated with risk for Alzheimer's disease (AD), but reported genome-wide significant loci do not account for all the estimated heritability and provide little information about underlying biological mechanisms. Genetic studies using intermediate quantitative traits such as biomarkers, or endophenotypes, benefit from increased statistical power to identify variants that may not pass the stringent multiple test correction in case-control studies. Endophenotypes also contain additional information helpful for identifying variants and genes associated with other aspects of disease, such as rate of progression or onset, and provide context to interpret the results from genome-wide association studies (GWAS). We conducted GWAS of amyloid beta (Aβ42), tau, and phosphorylated tau (ptau181) levels in cerebrospinal fluid (CSF) from 3146 participants across nine studies to identify novel variants associated with AD. Five genome-wide significant loci (two novel) were associated with ptau181, including loci that have also been associated with AD risk or brain-related phenotypes. Two novel loci associated with Aβ42 near GLIS1 on 1p32.3 (β = -0.059, P = 2.08 × 10-8) and within SERPINB1 on 6p25 (β = -0.025, P = 1.72 × 10-8) were also associated with AD risk (GLIS1: OR = 1.105, P = 3.43 × 10-2), disease progression (GLIS1: β = 0.277, P = 1.92 × 10-2), and age at onset (SERPINB1: β = 0.043, P = 4.62 × 10-3). Bioinformatics indicate that the intronic SERPINB1 variant (rs316341) affects expression of SERPINB1 in various tissues, including the hippocampus, suggesting that SERPINB1 influences AD through an Aβ-associated mechanism. Analyses of known AD risk loci suggest CLU and FERMT2 may influence CSF Aβ42 (P = 0.001 and P = 0.009, respectively) and the INPP5D locus may affect ptau181 levels (P = 0.009); larger studies are necessary to verify these results. Together the findings from this study can be used to inform future AD studies.

Entities:  

Keywords:  Alzheimer’s disease; Cerebrospinal fluid biomarkers; Endophenotype; Genome-wide association study

Mesh:

Substances:

Year:  2017        PMID: 28247064      PMCID: PMC5613285          DOI: 10.1007/s00401-017-1685-y

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  82 in total

1.  Principal components analysis corrects for stratification in genome-wide association studies.

Authors:  Alkes L Price; Nick J Patterson; Robert M Plenge; Michael E Weinblatt; Nancy A Shadick; David Reich
Journal:  Nat Genet       Date:  2006-07-23       Impact factor: 38.330

2.  Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies.

Authors:  Andrew D Skol; Laura J Scott; Gonçalo R Abecasis; Michael Boehnke
Journal:  Nat Genet       Date:  2006-01-15       Impact factor: 38.330

3.  Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer's research consortium study.

Authors:  Sid E O'Bryant; Stephen C Waring; C Munro Cullum; James Hall; Laura Lacritz; Paul J Massman; Philip J Lupo; Joan S Reisch; Rachelle Doody
Journal:  Arch Neurol       Date:  2008-08

Review 4.  Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease.

Authors:  J C Morris; J L Price
Journal:  J Mol Neurosci       Date:  2001-10       Impact factor: 3.444

5.  Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.

Authors:  Anne M Fagan; Catherine M Roe; Chengjie Xiong; Mark A Mintun; John C Morris; David M Holtzman
Journal:  Arch Neurol       Date:  2007-01-08

6.  Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.

Authors:  Trey Sunderland; Gary Linker; Nadeem Mirza; Karen T Putnam; David L Friedman; Lida H Kimmel; Judy Bergeson; Guy J Manetti; Matthew Zimmermann; Brian Tang; John J Bartko; Robert M Cohen
Journal:  JAMA       Date:  2003 Apr 23-30       Impact factor: 56.272

7.  MRI and CSF studies in the early diagnosis of Alzheimer's disease.

Authors:  M J de Leon; S DeSanti; R Zinkowski; P D Mehta; D Pratico; S Segal; C Clark; D Kerkman; J DeBernardis; J Li; L Lair; B Reisberg; W Tsui; H Rusinek
Journal:  J Intern Med       Date:  2004-09       Impact factor: 8.989

8.  Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition.

Authors:  John S K Kauwe; Carlos Cruchaga; Kevin Mayo; Chiara Fenoglio; Sarah Bertelsen; Petra Nowotny; Daniela Galimberti; Elio Scarpini; John C Morris; Anne M Fagan; David M Holtzman; Alison M Goate
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-09       Impact factor: 11.205

9.  Increasing CSF phospho-tau levels during cognitive decline and progression to dementia.

Authors:  Christin Andersson; Kaj Blennow; Ove Almkvist; Niels Andreasen; Peter Engfeldt; Sven-Erik Johansson; Maria Lindau; Maria Eriksdotter-Jönhagen
Journal:  Neurobiol Aging       Date:  2007-05-23       Impact factor: 4.673

10.  Role of genes and environments for explaining Alzheimer disease.

Authors:  Margaret Gatz; Chandra A Reynolds; Laura Fratiglioni; Boo Johansson; James A Mortimer; Stig Berg; Amy Fiske; Nancy L Pedersen
Journal:  Arch Gen Psychiatry       Date:  2006-02
View more
  65 in total

1.  Selective Neuronal Vulnerability in Alzheimer's Disease: A Network-Based Analysis.

Authors:  Jean-Pierre Roussarie; Vicky Yao; Patricia Rodriguez-Rodriguez; Rose Oughtred; Jennifer Rust; Zakary Plautz; Shirin Kasturia; Christian Albornoz; Wei Wang; Eric F Schmidt; Ruth Dannenfelser; Alicja Tadych; Lars Brichta; Alona Barnea-Cramer; Nathaniel Heintz; Patrick R Hof; Myriam Heiman; Kara Dolinski; Marc Flajolet; Olga G Troyanskaya; Paul Greengard
Journal:  Neuron       Date:  2020-06-29       Impact factor: 17.173

2.  Dr. Jekyll and Mr. Hyde: ApoE explains opposing effects of neuronal LRP1.

Authors:  Michael R Strickland; David M Holtzman
Journal:  J Clin Invest       Date:  2019-02-11       Impact factor: 14.808

3.  Alzheimer disease: A quantitative trait approach to GWAS pays dividends.

Authors:  Liana G Apostolova
Journal:  Nat Rev Neurol       Date:  2017-04-28       Impact factor: 42.937

4.  Genome-wide association study of Alzheimer's disease endophenotypes at prediagnosis stages.

Authors:  Jaeyoon Chung; Xulong Wang; Toru Maruyama; Yiyi Ma; Xiaoling Zhang; Jesse Mez; Richard Sherva; Haruko Takeyama; Kathryn L Lunetta; Lindsay A Farrer; Gyungah R Jun
Journal:  Alzheimers Dement       Date:  2017-12-20       Impact factor: 21.566

5.  Effects of Vitamin D Use on Outcomes of Psychotic Symptoms in Alzheimer Disease Patients.

Authors:  Lirong Wang; Jian Ying; Peihao Fan; Elise A Weamer; Mary Ann A DeMichele-Sweet; Oscar L Lopez; Julia K Kofler; Robert A Sweet
Journal:  Am J Geriatr Psychiatry       Date:  2019-03-27       Impact factor: 4.105

6.  Anterior Cingulate Structure and Perfusion is Associated with Cerebrospinal Fluid Tau among Cognitively Normal Older Adult APOEɛ4 Carriers.

Authors:  Chelsea C Hays; Zvinka Z Zlatar; M J Meloy; Jessica Osuna; Thomas T Liu; Douglas R Galasko; Christina E Wierenga
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

7.  The TMEM106B FTLD-protective variant, rs1990621, is also associated with increased neuronal proportion.

Authors:  Zeran Li; Fabiana H G Farias; Umber Dube; Jorge L Del-Aguila; Kathie A Mihindukulasuriya; Maria Victoria Fernandez; Laura Ibanez; John P Budde; Fengxian Wang; Allison M Lake; Yuetiva Deming; James Perez; Chengran Yang; Jorge A Bahena; Wei Qin; Joseph L Bradley; Richard Davenport; Kristy Bergmann; John C Morris; Richard J Perrin; Bruno A Benitez; Joseph D Dougherty; Oscar Harari; Carlos Cruchaga
Journal:  Acta Neuropathol       Date:  2019-08-27       Impact factor: 17.088

8.  The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimer's disease risk.

Authors:  Yuetiva Deming; Fabia Filipello; Francesca Cignarella; Claudia Cantoni; Simon Hsu; Robert Mikesell; Zeran Li; Jorge L Del-Aguila; Umber Dube; Fabiana Geraldo Farias; Joseph Bradley; John Budde; Laura Ibanez; Maria Victoria Fernandez; Kaj Blennow; Henrik Zetterberg; Amanda Heslegrave; Per M Johansson; Johan Svensson; Bengt Nellgård; Alberto Lleo; Daniel Alcolea; Jordi Clarimon; Lorena Rami; José Luis Molinuevo; Marc Suárez-Calvet; Estrella Morenas-Rodríguez; Gernot Kleinberger; Michael Ewers; Oscar Harari; Christian Haass; Thomas J Brett; Bruno A Benitez; Celeste M Karch; Laura Piccio; Carlos Cruchaga
Journal:  Sci Transl Med       Date:  2019-08-14       Impact factor: 17.956

9.  An APOE-independent cis-eSNP on chromosome 19q13.32 influences tau levels and late-onset Alzheimer's disease risk.

Authors:  Shuquan Rao; Mahdi Ghani; Zhiyun Guo; Yuetiva Deming; Kesheng Wang; Rebecca Sims; Canquan Mao; Yao Yao; Carlos Cruchaga; Dietrich A Stephan; Ekaterina Rogaeva
Journal:  Neurobiol Aging       Date:  2018-01-03       Impact factor: 4.673

Review 10.  Transcription factor GLIS3: Critical roles in thyroid hormone biosynthesis, hypothyroidism, pancreatic beta cells and diabetes.

Authors:  David W Scoville; Hong Soon Kang; Anton M Jetten
Journal:  Pharmacol Ther       Date:  2020-07-18       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.